pharmaphorum

NOVEMBER 2, 2021

In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform. billion in milestones – and covers drug candidates against up to four disease targets.

Protein 98

Protein Licensing Licensing Drugs 98

Pharmaceutical Technology

OCTOBER 21, 2022

DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). Wide-ranging drug discovery capabilities of AbbVie will be used by DJS for making antibody therapies and new biology insights against targets such as GPCRs.

Antibody 217

Antibody Protein Licensing Licensing 217

pharmaphorum

NOVEMBER 15, 2022

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases. The post Roche deepens ties with Jnana with a second licensing deal appeared first on.

Licensing 105

Licensing Licensing Protein Genetics 105

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti.

Development 130

Development Drugs Licensing Licensing 130

pharmaphorum

AUGUST 25, 2021

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five drug targets. The protein degrader approach has attracted a series of big-ticket licensing deals in the last couple of years.

Protein 69

Protein Licensing Licensing Drugs 69

XTalks

OCTOBER 22, 2024

Astellas Pharma has won approval from the US Food and Drug Administration (FDA) for Vyloy (zolbetuximab) as a first-line treatment for adults with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The drug is specifically indicated for patients whose tumors are HER2-negative and express claudin 18.2 months from 15.5

FDA Approval 105

FDA Approval Drugs Licensing Licensing 105

Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278

Marketing Production Drugs Trials 278

pharmaphorum

SEPTEMBER 2, 2020

The drug, JTX-1811, is a monoclonal antibody designed to selectively deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. . The drug targets CCR8, a chemokine receptor enriched on TITR cells. The results spooked investors and caused shares in Jounce to fall, but the drug is continuing through phase 2 trials.

Licensing 71

Licensing Licensing Antibody Immune Response 71

Pharmaceutical Technology

SEPTEMBER 22, 2022

Avrobio has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, AVR-RD-04, designed to treat cystinosis. AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein.

Gene Therapy 147

Gene Therapy Gene Protein Clinical Trials 147

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

pharmaphorum

JUNE 21, 2022

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of the disease transthyretin amyloidosis (ATTR) it licensed from Ionis in a $3.6 The post AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen appeared first on.

Drugs 111

Drugs Protein Production Marketing 111

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. Bamlanivimab is directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.

Drugs 111

Drugs Antibody FDA Approval Pharma Companies 111

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pharmaceutical Technology

NOVEMBER 1, 2022

An oral inhibitor of exportin 1 (XPO1), Nexpovio works by selectively attaching to hindering the nuclear export protein XPO1. It prevents the tumour suppressor, growth regulatory and anti-inflammatory proteins’ nuclear export, causing their build-up in the nucleus and boosting their anti-cancer activity in the cell.

Protein 130

Protein FDA Approval Production Licensing 130

Pharma Times

OCTOBER 14, 2020

Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development

Licensing 69

Licensing Licensing Protein Development 69

pharmaphorum

APRIL 8, 2022

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. As it is in the very early stages Jazz’s licensing deal is heavily back-weighted, but does include $1.26 Image by Lukas Bieri from Pixabay .

Drugs 105

Drugs Immune Response Licensing Licensing 105

pharmaphorum

DECEMBER 7, 2021

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR). billion in milestones depending on sales levels if the antisense-based drug reaches the market.

Licensing 59

Licensing Licensing Drugs Marketing 59

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MP-0310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MP-0310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Protein 52

Protein Licensing Licensing Containment 52

Pharmaceutical Technology

AUGUST 14, 2022

Novavax and its partner SK bioscience have obtained a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), to be used in adolescents of the age 12 to 17 years.

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

pharmaphorum

MAY 12, 2022

Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down.

Protein 52

Protein Genome Genomics Drugs 52

pharmaphorum

JANUARY 7, 2022

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months. Tafamidis is thought to work by stabilising the misfolded proteins. The new agreement comes just days after AZ closed a $3.1

Antibody 116

Antibody Licensing Licensing Protein 116

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pharmaceutical Technology

FEBRUARY 21, 2023

The US Food and Drug Administration (FDA) has accepted a priority review of the biologics license application (BLA) for Regeneron Pharmaceuticals ’ pozelimab to treat children and adults with ultra-rare CHAPLE disease. C5 is a protein that is involved in the activation of the complement system.

Antibody 130

Antibody FDA Approval Licensing Licensing 130

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. In the EU, loncastuximab tesirine has orphan drug designation for the treatment of DLBCL, a form of non-Hodgkin lymphoma (NHL).

Licensing 52

Licensing Licensing Sales Marketing 52

pharmaphorum

SEPTEMBER 13, 2022

Chiesi’s involvement with Lamzede dates back to 2013, when it acquired the drug’s original developer Zymenex and used it as the foundation for a protein-based therapeutics division. The post FDA starts review of first drug for alpha-mannosidosis, from Chiesi appeared first on.

Drugs 105

Drugs Licensing Licensing Production 105

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. Under the terms of the agreement, POINT will complete the study and, if positive, Lantheus will take responsibility for submitting the drug for approval.

Licensing 52

Licensing Licensing FDA Approval Trials 52

pharmaphorum

JANUARY 11, 2023

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and immunology. before disease-related proteins are expressed). before disease-related proteins are expressed).

Protein 105

Protein Regulation FDA Approval Licensing 105

Pharmaceutical Technology

AUGUST 23, 2022

Pfizer and BioNTech have filed an application seeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a booster dosage of an Omicron BA.4/BA.5-adapted It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Delveinsight

AUGUST 18, 2020

Sanofi had earlier licensed-in Principia’s experimental multiple sclerosis treatment ‘168; the late-stage pemphigus treatment Rilzabrutinib; and PRN473, a topical BTK inhibitor. The drug is approved in Canada, Japan, and Switzerland for NMOSD. Sanofi had been in business-relation with Principia for a long time now.

Licensing 52

Licensing Licensing Protein Antibody 52

Pharmaceutical Technology

FEBRUARY 7, 2023

The US Food and Drug Administration (FDA) has accepted Sandoz’s biologics license application (BLA) for its proposed biosimilar denosumab. The human monoclonal antibody denosumab has been designed to bind to osteoclasts activator, RANKL protein.

Packaging 130

Packaging Packaging Medicine Licensing 130

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells.

Licensing 52

Licensing Licensing Drugs Development 52

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

Pharmaceutical Technology

APRIL 24, 2023

Everest Medicines launched its immunoglobulin A (IgA) nephropathy drug Tarpeyo (Nefecon) (budesonide) in China’s Hainan Boao Pilot Zone, making it the first therapy available in this disease area. This follows the drug’s successful commercial launch in the UK, US and Europe.

Drugs 130

Drugs Medicine Production Marketing 130